Clinical Trial Update: Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Acthar for focal segmental glomerulosclerosis in patients undergoing renal transplantation has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Segmental Glomerulosclerosis

Drugs mentioned

• Acthar (repository corticotropin injection)

Snippet

Sponsor: University of Colorado, Denver | Conditions: FSGS | Phase 3 | Status: COMPLETED | Results posted: 2026-03-23